Acute renal failure and alendronate

Zazgórnik, J; Grafinger, P; Biesenbach, Georg; Hubmann, Rainer; Fridrik, Michael A.

doi:10.1093/ndt/12.12.2797

Cited by 23 publications

(14 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…bisphosphonates for the treatment of multiple myeloma and Paget's disease [49,50] as well as after inadvertent overdose [51], but this is rare if drugs are administered as indicated. Increases in serum creatinine levels are usually not of clinical significance.…”

Section: Safetymentioning

confidence: 99%

Bone Loss and Fracture Risk Associated with Cancer Therapy

2006

View full text Add to dashboard Cite

Background. Cancer patients experience osteoporosis resulting from accelerated loss of bone mineral density (BMD) caused by their treatment. Such bone loss greatly increases the risk for fracture and can have other serious effects on quality of life.Methods. In the current report, the author focuses on studies of cancer therapy-associated bone loss, its prevalence and pathogenesis, and resulting clinical impact. Options for management and prevention are also reviewed, including treatment guidelines where available.Results. A variety of cancer therapies, including hormonal therapy, chemotherapy, and glucocorticoids, affect gonadal hormone production, which increases bone resorption and decreases BMD. Such bone loss occurs more rapidly and to a greater degree than normal age-related osteoporosis, increases the risk for fracture

show abstract

Section: Safetymentioning

confidence: 99%

Bone Loss and Fracture Risk Associated with Cancer Therapy

2006

View full text Add to dashboard Cite

show abstract

“…Sporadic episodes of acute and subacute renal failure have been reported [7][8][9][10][11][12][13], whereas hypocalcemia has not yet been the subject of detailed research.…”

Section: Introductionmentioning

confidence: 99%

High Incidence of Hypocalcemia and Serum Creatinine Increase in Patients with Bone Metastases Treated with Zoledronic Acid

et al. 2009

View full text Add to dashboard Cite

Background. Zoledronic acid belongs to the new generation of bisphosphonates with demonstrated clinical benefit for the treatment of bone metastases from different kinds of neoplasms. Hypocalcemia and serum creatinine elevation are expected adverse events during this therapy. The monitoring of serum calcium and creatinine is therefore recommended. The primary aim of this study was to establish the actual incidence of hypocalcemia and serum creatinine elevation during treatment with zoledronic acid. Skeletal-related events and side effects were also assessed.Methods. Serum creatinine and calcium levels were evaluated in 240 consecutive patients (83 males, 157 females; mean age, 62 years) with metastatic bone lesions from different solid tumors treated with zoledronic acid.Results. Overall, 93 of 240 patients (38.8%) developed

show abstract

“…However, all BPs have the potential for adversely affecting renal function; indeed, sporadic episodes of acute and subacute renal failure have been described for several i.v. BPs [6][7][8][9][10][11][12][13]. However, this toxicity is extremely rare when the agents are administered at their recommended doses and infusion rates.…”

Section: Introductionmentioning

confidence: 99%

Renal Safety and Efficacy of i.v. Bisphosphonates in Patients with Skeletal Metastases Treated for up to 10 Years

Guarneri

Donati²,

Nicolini

et al. 2005

The Oncologist

View full text Add to dashboard Cite

Introduction. Bisphosphonates (BPs) delay the onset or reduce the incidence of skeletal complications in patients with bone metastases. However, there are few data on the renal safety and activity of i.v. BPs beyond 2 years of administration.Materials and Methods. We retrospectively analyzed serum creatinine (SCr) levels and skeletal-related events (SREs) in cancer patients receiving i.v. BPs for ≥24 months. All patients received 90 mg pamidronate every 3-4 weeks. Pre-and post-treatment SCr levels and the peak levels attained were recorded. A notable SCr increase was defined as: an increase >0.5 mg/dl for patients with baseline SCr <1.4 mg/dl; an increase >1 mg/dl for patients with baseline SCr >1.4 mg/dl; or doubling over baseline. The following parameters were also analyzed: the proportion of patients with at least one SRE, the distribution of each type of SRE, the time to first SRE, and the skeletal morbidity rate (SMR).Results. Fifty-seven patients with bone metastases resulting from breast cancer (BC) (n = 48), multiple myeloma (n = 7), renal cell carcinoma (n = 1), and prostate cancer (n = 1) were evaluated. The median age at the start of treatment was 57 years (range, 27-81); 25% of the patients were >70 years old. Forty-three patients

show abstract

Acute renal failure and alendronate

Cited by 23 publications

References 0 publications

Bone Loss and Fracture Risk Associated with Cancer Therapy

Bone Loss and Fracture Risk Associated with Cancer Therapy

High Incidence of Hypocalcemia and Serum Creatinine Increase in Patients with Bone Metastases Treated with Zoledronic Acid

Renal Safety and Efficacy of i.v. Bisphosphonates in Patients with Skeletal Metastases Treated for up to 10 Years

Contact Info

Product

Resources

About